InsuSense Therapeutics (IST) is a product-focused biotechnology company based on novel breakthrough science in diabetes biology, which has the potential to quantum leap to important new Type 2 diabetes therapeutics. One of the most important features in the pathophysiology of Type 2 diabetes is insulin resistance. The IP position of the company consists of different natural circulating and cellular proteins that increase insulin action at the level of target tissues. It is the aim to refine these proteins into therapeutics acting as potent and safe insulin sensitizers for type 2 diabetes.
The foundation of InsuSense comes from the pioneering science of Anders Nykjaer. Professor Nykjaer has developed the field of Vps10p-domain receptors (Sortilins). By virtue of the direct association of the Vps10p-domain with the insulin receptor, combined with the already observed effects on insulin sensitization, the discovery may have the potential to represent the next significant diabetes treatment mechanism.
IST’s vision is to bring forward novel therapeutics, based on unique scientific understanding and intellectual property of the company, offering patients superior long term management of their diabetes disease.
IST is currently pursuing this by identifying active proteins based on the naturally occurring Vps10p-domains and manufacturing these on a relevant scale.